Ubiquitin-dependent remodeling of the actin cytoskeleton drives cell fusion.
CUL3
EPS8
actin
actin bundle
cell fusion
monoubiquitylation
ubiquitin
Journal
Developmental cell
ISSN: 1878-1551
Titre abrégé: Dev Cell
Pays: United States
ID NLM: 101120028
Informations de publication
Date de publication:
08 03 2021
08 03 2021
Historique:
received:
16
06
2020
revised:
14
11
2020
accepted:
24
01
2021
pubmed:
21
2
2021
medline:
31
8
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Cell-cell fusion is a frequent and essential event during development, and its dysregulation causes diseases ranging from infertility to muscle weakness. Fusing cells need to repeatedly remodel their plasma membrane through orchestrated formation and disassembly of actin filaments, but how the dynamic reorganization of the cortical actin cytoskeleton is controlled is still poorly understood. Here, we identified a ubiquitin-dependent toggle switch that establishes reversible actin bundling during mammalian cell fusion. We found that EPS8-IRSp53 complexes stabilize cortical actin bundles at sites of cell contact to promote close membrane alignment. EPS8 monoubiquitylation by CUL3
Identifiants
pubmed: 33609460
pii: S1534-5807(21)00074-5
doi: 10.1016/j.devcel.2021.01.016
pii:
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
BAIAP2 protein, human
0
CUL3 protein, human
0
Cullin Proteins
0
EPS8 protein, human
0
Nerve Tissue Proteins
0
Ubiquitin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
588-601.e9Subventions
Organisme : NIH HHS
ID : S10 OD021828
Pays : United States
Organisme : NIH HHS
ID : S10 OD018174
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR025622
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests M.R. is a co-founder and consultant to Nurix Therapeutics, a publicly traded company in the ubiquitin space. M.R. is a member of the scientific advisory board of Monte Rosa Therapeutics.